Holen Sie sich die Stockscreener-App
8.95
7.73%
-0.75
Schlusskurs vom Vortag:
$9.70
Offen:
$9.78
24-Stunden-Volumen:
34,441
Relative Volume:
7.87
Marktkapitalisierung:
$5.04M
Einnahmen:
$7.10M
Nettoeinkommen (Verlust:
$-39.43M
KGV:
-9.5213
EPS:
-0.94
Netto-Cashflow:
$-46.50M
1W Leistung:
+5.29%
1M Leistung:
-98.35%
6M Leistung:
-86.69%
1J Leistung:
-90.34%
1-Tages-Spanne:
$8.49
$9.78
1-Wochen-Bereich:
$7.26
$10.20
52-Wochen-Spanne:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Firmenname
Spruce Biosciences Inc
Sektor
Branche
Telefon
(415) 655-4168
Adresse
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Vergleichen Sie SPRB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
8.95 | 5.46M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-12-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-03-14 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-03-14 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-03-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-14 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-14 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-21 | Eingeleitet | Guggenheim | Buy |
| 2021-12-17 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | The Benchmark Company | Speculative Buy |
| 2021-11-16 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | Cowen | Outperform |
| 2020-11-03 | Eingeleitet | Credit Suisse | Outperform |
| 2020-11-03 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-11-03 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Spruce Biosciences Inc Aktie (SPRB) Neueste Nachrichten
Critical Contrast: Spruce Biosciences (SPRBD) vs. Its Rivals - Defense World
Reviewing Spruce Biosciences (SPRBD) & Its Rivals - Defense World
Spruce Biosciences, Inc.(NasdaqCM: SPRB) added to NASDAQ Composite Index - MarketScreener
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market - BioSpace
Spruce Biosciences resumes Nasdaq trading today - Investing.com
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B - Investing News Network
One new option listing and two option delistings on September 5th - TipRanks
Head to Head Contrast: Spruce Biosciences (SPRBD) versus Its Peers - Defense World
Spruce Biosciences (SPRBD) & The Competition Critical Review - Defense World
Spruce Biosciences (SPRBD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - sharewise.com
Spruce Biosciences (NASDAQ:SPRB) Trading Down 1.6% – What’s Next? - Defense World
Contrasting Spruce Biosciences (SPRBD) and The Competition - Defense World
Financial Analysis: MusclePharm (OTCMKTS:MSLP) & Spruce Biosciences (NASDAQ:SPRB) - Defense World
Research Analysts Set Expectations for OTC:SPRBD Q1 Earnings - Defense World
Spruce Biosciences Reports Promising Clinical Advances - TipRanks
Cautious Optimism for Spruce Biosciences Amid Promising Data and Financial Uncertainty - TipRanks
Head to Head Survey: Zomedica (OTC:ZOMDF) vs. Spruce Biosciences (NASDAQ:SPRB) - Defense World
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB) - BioSpace
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - BioSpace
Spruce Biosciences reports positive long-term data for MPS IIIB therapy - Investing.com Nigeria
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfil - StreetInsider
Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday - Defense World
Head to Head Analysis: Gemini Therapeutics (NASDAQ:GMTX) and Spruce Biosciences (NASDAQ:SPRB) - Defense World
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Press Release: Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - 富途牛牛
Spruce Biosciences (NASDAQ:SPRB) Shares to Reverse Split on Monday, August 4th - Defense World
Spruce Biosciences Announces Reverse Stock Split Plan - The Globe and Mail
Spruce Biosciences to enact 1-for-75 reverse stock split - MSN
Spruce Biosciences to implement 1-for-75 reverse stock split - Investing.com
Spruce Biosciences Announces Reverse Stock Split - Business Wire
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder - The Manila Times
Spruce Biosciences (SPRB) Advances in Phase 2 Depression Treatme - GuruFocus
Spruce Biosciences (NASDAQ:SPRB) Trading Up 5.7% – Here’s What Happened - Defense World
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter
Ultragenyx hit again, this time with a CRL in rare disease - BioWorld MedTech
Spruce Biosciences (SPRB) Gains Investor Attention with Significant Interest Surge | SPRB Stock News - GuruFocus
Spruce Biosciences gets conditional approval to resume trading on Nasdaq Capital Market - MSN
Spruce Biosciences (NASDAQ:SPRB) versus Pharmaxis (OTCMKTS:PXSLY) Head-To-Head Analysis - Defense World
Congenital Adrenal Hyperplasia Treatment Market Outlook Influenced by Gene Therapy Innovations 2025 - openPR.com
SPRB ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Spruce Biosciences, Inc. - ACCESS Newswire
BriaCell Therapeutics (OTCMKTS:BCTXF) vs. Spruce Biosciences (NASDAQ:SPRB) Head-To-Head Survey - Defense World
Congenital Adrenal Hyperplasia Pipeline Insight, 2025: - openPR.com
Spruce Biosciences (SPRB) Secures Nasdaq Approval for Relisting - GuruFocus
Spruce Biosciences Announces Conditional Nasdaq Approval to Resu - GuruFocus
# Spruce Biosciences to resume Nasdaq trading pending stock split approval By Investing.com - Investing.com South Africa
Finanzdaten der Spruce Biosciences Inc-Aktie (SPRB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):